Kopran Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,318 Cr
- P/E
- 33.53
- ROE
- 4.91%
- PEG
- -17.93
- Price to sales
- 1.66
- Debt to equity
- 0.39
- 52W high / low
- ₹291 / ₹108
- Sales growth (5Y)
- 6.74%
- EBITDA margin
- 10.32%
- Net profit margin
- 3.78%
- Promoter holding
- 41.83%
- Sales (last year)
- ₹794 Cr
Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.
Guidance scorecard · Q2 FY27 call
What Kopran's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ3 FY25 call
10–20%- Kopran Laboratories operates in a fast-growing Indian diagnostic industry expected to grow at a CAGR of 14% over the next 5 years, reaching $25 billion by FY '28 and nearly tripling by 2034.
- Kopran Labs has shown strong past growth, increasing top line threefold from INR35 crores to INR103 crores in 4 years.
- The diagnostic segment is expected to participate in this industry growth, with new divisions added recently to drive further revenue.
- South region operations, started about 3 years ago, hold significant growth potential.
- Annual addition of 20-25 diagnostic machines is expected, supporting steady volume growth.
2 more points from Kopran's call on revenue
Create a free account to keep reading this call
MarginsQ3 FY25 call
FlatSee what Kopran said on margins — free account, 30 seconds.
CapexQ3 FY25 call
Planned- Kopran Laboratories has a current capital investment approach involving approximately 120 machines deployed on a contracted basis.
- Annually, they add about 20-25 machines to their reagent rental business.
- For the current year mentioned, 23-24 machines were added, with a possibility of 1-2 more before year-end.
- The expected annual investment in machines is around INR 7 to 8 crores.
- All these capital expenditures are funded through internal accruals, supported by a substantial cash reserve.
2 more points from Kopran's call on capex
Create a free account to keep reading this call
FundraisingQ3 FY25 call
None plannedSee what Kopran said on fundraising — free account, 30 seconds.
Order bookQ3 FY25 call
- Kopran Laboratories has close to 120 machines deployed across India on a contracted basis.
- Each machine is part of a long-term contract averaging around 5 to 5.5 years.
- The company typically adds 20 to 25 new machines annually; 23-24 machines were added in the current year.
- These contracts ensure recurrent purchase of consumables, forming an annuity-like revenue stream.
- Kopran anticipates continuing this orderbook growth annually, funded through internal accruals.
- They maintain warehousing and cold chain logistics to support ongoing orders.
2 more points from Kopran's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Kopran latest results (Sep 2026)
Revenue
₹211 Cr
+79.17% YoY
Net profit
₹4 Cr
Operating margin
7.29%
EPS
₹0.91
Kopran shareholding (Sep 2026)
Promoters
41.83%
−2.60 pp QoQ
FIIs
0.91%
+0.40 pp QoQ
DIIs
0.00%
unchanged QoQ
Public
57.26%
+2.20 pp QoQ
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,142 Cr | 34.2 | |
| 2 | 40%+ | Up 2%+ | ₹489 Cr | 16.7 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,464 Cr | 1614.0 | |
| 5 | 40%+ | Flat | ₹9,050 Cr | 34.8 | |
| 6 | 40%+ | Flat | ₹4,493 Cr | — |
Sign up free to see every company in the sector ranking and track Kopran.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Kopran
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Kopran
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 44.49% | 44.49% | 44.49% | 44.49% | 44.45% | 44.42% | 44.43% | 44.43% | 44.43% | 44.43% | 44.43% | 41.83% |
| FIIs + | 0.48% | 0.84% | 0.68% | 1.31% | 0.86% | 1.11% | 0.76% | 0.60% | 0.36% | 0.57% | 0.51% | 0.91% |
| DIIs + | 0.14% | 1.20% | 0.14% | 0.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public + | 54.88% | 53.47% | 54.68% | 53.98% | 54.68% | 54.45% | 54.81% | 54.99% | 55.21% | 55.01% | 55.06% | 57.26% |
| No. of Shareholders | 51,636 | 50,850 | 51,492 | 57,154 | 60,560 | 58,652 | 60,194 | 62,222 | 60,886 | 58,639 | 56,925 | 52,924 |
Financials of Kopran
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 152.59 | 158.92 | 186.08 | 139.44 | 151.56 | 166.24 | 172.36 | 135.22 | 117.91 | 194.28 | 234.02 | 153.99 | 211.26 |
| YoY Sales growth | +30.45% | +0.58% | +24.99% | +19.18% | -0.68% | +4.61% | -7.37% | -3.03% | -22.20% | +16.87% | +35.77% | +13.88% | +79.17% |
| Expenses + | 129.76 | 135.34 | 164.39 | 121.28 | 136.83 | 146.39 | 155.27 | 121.09 | 123.19 | 176.52 | 201.08 | 138.18 | 195.85 |
| Operating Profit | 22.83 | 23.58 | 21.69 | 18.16 | 14.73 | 19.85 | 17.09 | 14.13 | -5.28 | 17.76 | 32.94 | 15.81 | 15.41 |
| OPM % | 14.96% | 14.84% | 11.66% | 13.02% | 9.72% | 11.94% | 9.92% | 10.45% | -4.48% | 9.14% | 14.08% | 10.27% | 7.29% |
| Other Income + | 0.13 | 2.43 | 9.67 | 2.63 | 1.00 | 0.17 | 3.26 | 2.56 | 0.03 | 0.07 | 0.09 | 2.05 | 0.62 |
| Interest | 1.94 | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 | 2.09 | 2.67 | 3.17 | 3.28 | 4.25 |
| Depreciation | 2.77 | 3.27 | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 | 4.28 | 4.42 | 4.52 | 5.77 | 5.89 |
| Profit before tax | 18.25 | 20.50 | 25.18 | 14.74 | 9.65 | 13.86 | 13.71 | 9.89 | -11.62 | 10.74 | 25.34 | 8.81 | 5.89 |
| Tax % | 24.55% | 23.02% | 26.01% | 24.69% | 23.42% | 24.96% | 29.39% | 24.67% | -14.63% | 13.04% | 25.57% | 23.84% | 25.47% |
| Net Profit + | 13.77 | 15.79 | 18.62 | 11.10 | 7.38 | 10.40 | 9.68 | 7.45 | -9.92 | 9.34 | 18.87 | 6.70 | 4.39 |
| EPS in Rs | 2.86 | 3.28 | 3.86 | 2.30 | 1.53 | 2.16 | 2.01 | 1.54 | -2.06 | 1.94 | 3.91 | 1.39 | 0.91 |
Financials of Kopran
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 615 | 630 | 681 | 794 |
| Sales growth | +8% | -9% | +5% | +1% | +14% | +0% | +37% | -3% | +15% | +12% | +2% | +8% | +34% |
| Expenses + | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 540 | 557 | 619 | 712 |
| Operating Profit | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 74 | 73 | 62 | 82 |
| OPM % | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 12% | 12% | 9% | 10% |
| Other Income + | -48 | 1 | 11 | 9 | 3 | -0 | 18 | 11 | 3 | 15 | 4 | 0 | 3 |
| Interest | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 9 | 9 | 10 | 13 |
| Depreciation | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 13 | 16 | 17 | 21 |
| Profit before tax | -39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 68 | 52 | 34 | 51 |
| Tax % | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | 25% | 26% | 25% | |
| Net Profit + | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 51 | 39 | 26 | 39 |
| EPS in Rs | -9.52 | 2.48 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 10.57 | 7.99 | 5.33 | 8.15 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% | 28% | 38% | 56% |
Financials of Kopran
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 43 | 43 | 43 | 43 | 43 | 43 | 48 | 48 | 48 | 48 | 48 | 48 |
| Reserves | 49 | 57 | 81 | 101 | 125 | 146 | 202 | 378 | 391 | 443 | 470 | 482 | 480 |
| Borrowings + | 86 | 80 | 95 | 89 | 97 | 88 | 66 | 75 | 75 | 99 | 148 | 153 | 208 |
| Other Liabilities + | 99 | 84 | 78 | 82 | 85 | 92 | 128 | 110 | 135 | 153 | 178 | 225 | 227 |
| Total Liabilities | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 908 | 964 |
| Fixed Assets + | 102 | 101 | 104 | 104 | 113 | 111 | 112 | 151 | 165 | 182 | 208 | 346 | 378 |
| CWIP | 1 | 3 | 6 | 10 | 24 | 30 | 43 | 36 | 70 | 97 | 113 | 25 | 12 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 172 | 160 | 187 | 201 | 214 | 229 | 284 | 425 | 415 | 465 | 522 | 537 | 574 |
| Total Assets | 275 | 264 | 298 | 315 | 351 | 370 | 439 | 611 | 650 | 743 | 844 | 908 | 964 |
Financials of Kopran
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 46 | 29 | 16 | 26 | 25 | 31 | 60 | -33 | 34 | 43 | 42 | 67 |
| Cash from Investing Activity + | -10 | -9 | -18 | -11 | -25 | -13 | -25 | -84 | -13 | -44 | -56 | -65 |
| Cash from Financing Activity + | -37 | -19 | 2 | -15 | -1 | -18 | -35 | 123 | -20 | 1 | 26 | -21 |
| Net Cash Flow | -0 | 0 | -0 | -0 | -0 | 0 | 0 | 5 | 2 | 1 | 11 | -19 |
| Free Cash Flow | 35 | 18 | -0 | 14 | -6 | 17 | 43 | -76 | -27 | -13 | -17 | -0 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 147% | 95% | 47% | 94% | 63% | 82% | 93% | -17% | 90% | 77% | 76% | 117% |
Financials of Kopran
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 70 | 86 | 75 | 88 | 94 | 89 | 97 | 108 | 126 | 125 | 141 |
| Inventory Days | 78 | 119 | 122 | 138 | 129 | 154 | 121 | 202 | 133 | 126 | 153 | 137 |
| Days Payable | 119 | 115 | 95 | 118 | 90 | 95 | 104 | 84 | 89 | 103 | 108 | 131 |
| Cash Conversion Cycle | 50 | 74 | 113 | 96 | 127 | 153 | 106 | 215 | 152 | 149 | 170 | 146 |
| Working Capital Days | 9 | 34 | 43 | 60 | 70 | 79 | 81 | 158 | 139 | 131 | 113 | 91 |
| ROCE % | 14% | 14% | 19% | 14% | 16% | 14% | 30% | 21% | 8% | 14% | 10% | 7% |
Guidance history
How Kopran's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q3 FY25 call → | 10–20% | Flat | Planned | None planned | — |
| Q3 FY25 call → | 10–20% | Up 2%+ | Planned | None planned | — |
| Q2 FY25 call → | 10–20% | Flat | Planned | — | — |
| Q1 FY25 call → | 20–40% | Up 2%+ | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
46 out of 100 — Steady
Over the past year its share price has moved roughly in the middle of the stocks we track.
| Period | Share price change | Better than … of 1,947 stocks |
|---|---|---|
| Last 12 months | +95.7% | 93% |
| Last 6 months | +58.3% | 91% |
| Last 3 months | +35.3% | 96% |
The price is 21.4% below its all-time high of ₹346.8 (13 Sept 2024). Stocks more than 20% below their peak have their score halved, so 93 became 46.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,947 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Kopran: 0.4 × 93 + 0.4 × 91 + 0.2 × 96 = 93, halved to 46 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 17 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Kopran: frequently asked questions
What is Kopran share price today?
Kopran last traded at ₹272.66, with a market capitalisation of ₹1,318 Cr and a P/E ratio of 33.5.
What were Kopran's latest quarterly results?
For the quarter ended Sep 2026, Kopran reported revenue of ₹211 Cr (+79.17% year on year) and net profit of ₹4 Cr, with an operating margin of 7.29%.
Is Kopran's profit growing?
Net profit was ₹4 Cr in Sep 2026 against ₹-10 Cr in Sep 2025.
What is Kopran's EPS?
Kopran's earnings per share for the quarter ended Sep 2026 was ₹0.91.
What is the promoter holding in Kopran?
Promoters held 41.83% of Kopran in Sep 2026 (−2.60 pp versus Jun 2026).
How much do FIIs and DIIs hold in Kopran?
In Sep 2026, foreign institutional investors held 0.91% and domestic institutions (including mutual funds) held 0.00% of Kopran.
What is Kopran's ROE and ROCE?
Kopran's return on equity is 4.91% and its return on capital employed is 6.65%.
Does Kopran pay a dividend?
Yes. Kopran's dividend yield is 1.15% at the current price. The full payout history is on the Kopran dividends page.
Which sector does Kopran belong to?
Kopran is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Kopran's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Kopran's management.
How does Arthneeti AI analyse Kopran?
Arthneeti reads Kopran's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
